National Institute for Health and Care Excellence (NICE)

news

NICE recommends Apremilast for treating psoriatic arthritis

11 October 2016 | By Niamh Louise Marriott, Digital Content Producer

The National Institute for Health and Care Excellence (NICE) has released draft guidance recommending Apremilast for the treatment of psoriatic arthritis in adults. This appraisal was a rapid review of the NICE technology appraisal guidance published in December 2015. It focused on cost-effectiveness analyses using a patient access scheme agreement, which provides apremilast at…

news

‘Game-changing’ immunotherapy doubles head and neck cancer survival

10 October 2016 | By Niamh Louise Marriott, Digital Content Producer

An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...

news

NICE plans to recommend extra ‘triple therapy’ type 2 diabetes drug

7 October 2016 | By Niamh Louise Marriott, Digital Content Producer

Once final guidance is published, dapagliflozin will join two other similar drugs, empagliflozin and canagliflozin, as options for triple therapy...

news

NICE recommends first drug for the Cancer Drugs Fund

4 October 2016 | By Niamh Louise Marriott, Digital Content Producer

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance which says osimertinib (Tagrisso, AstraZeneca) should be made available to some people with lung cancer through the Cancer Drugs Fund (CDF).

news

NICE recommends Novartis’ ankylosing spondylitis drug

29 September 2016 | By Niamh Louise Marriott, Digital Content Producer

NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...

news

NICE recommends new rare inherited bone disorder drug for children

28 September 2016 | By Niamh Louise Marriott, Digital Content Producer

The drug is the first treatment to target hypophosphatasia, a condition affecting the development of bone, and could allow children to lead a normal life...

news

NICE does not recommend obinutuzumab to treat follicular lymphoma

20 September 2016 | By Niamh Louise Marriott, Digital Content Producer

Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment...

news

NICE says coil is more effective than pill as emergency contraception

8 September 2016 | By Niamh Louise Marriott, Digital Content Producer

The coil is the most effective form of emergency contraception for up to 5 days after unprotected sex or within 5 days of expected ovulation...

news

NICE says Roche’s skin cancer drug not cost effective

6 September 2016 | By Niamh Louise Marriott, Digital Content Producer

The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year...

news

NICE recommends Bayer’s prostate cancer drug for routine NHS use

2 September 2016 | By Niamh Louise Marriott, Digital Content Producer

NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer...

article

Re-evaluating the Cancer Drugs Fund: Out with the old, in with the new

31 August 2016 | By Niamh Louise Marriott, Digital Content Producer

In April of this year, NICE started to assess the cost and clinical effectiveness of every drug currently in the old cancer drugs fund...

news

NICE approves CDF drugs for routine NHS use

24 August 2016 | By National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) issued final guidance recommending two drugs for routine use within the NHS: Bosutinib (Bosulif, Pfizer) for treating some patients with leukaemia and Pemetrexed (Alimta, Eli Lilly) for treating some patients with lung cancer...

news

NICE says Bayer’s liver cancer drug is not cost-effective

24 August 2016 | By The National Institute for Health and Care Excellence (NICE)

NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available...

news

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

18 August 2016 | By The National Institute for Health and Care Excellence (NICE)

In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective. 

news

NICE recommends Pfizer’s lung cancer drug after price drop

18 August 2016 | By The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…